Health Institutes of Türkiye

What Health Institutes of Türkiye does

Health Institutes of Türkiye (Türkiye Sağlık Enstitüleri Başkanlığı, TÜSEB) is a government state institution established under the Republic of Turkey Ministry of Health, coordinating health research, biotechnology, vaccine development, clinical trials, genomics, and healthcare quality accreditation across Turkey. Founded in 2015 with 186 employees, TÜSEB operates as an integrated platform comprising 9 specialized institutes covering maternal and child health, vaccines, biotechnology, traditional and complementary medicine, public health and chronic diseases, cancer, healthcare quality and accreditation, health policy, and health data and AI applications. The organization also operates 4 major research centers: the National Genome Center (TUGEM), Aziz Sancar Research Center (ASAM), Istanbul Experimental Research Development and Training Center (İDEA), and BİYAŞAM. Notable technical outputs include the successful development of TURKOVAC, Turkey's indigenous COVID-19 vaccine, and the first 10-day GMP-compliant CAR-T cell production process. The technology stack is anchored by the TÜSEB Information and Management System (TBYS) for project and call management, supported by Technology Transfer Office branches at multiple city hospitals to facilitate health technology commercialization.

TÜSEB's primary customer segments include Turkish universities and research institutions (for research funding and technology transfer), public healthcare facilities and hospitals (for clinical research support and accreditation), the pharmaceutical industry (Sanofi, Roche, Pfizer, Novo Nordisk partnerships for clinical trials), medical device manufacturers (ARTED collaboration for local production), and health policy makers (for evidence-based analysis). The revenue model relies on three streams: government budget allocation from the Ministry of Health as the primary funding source, project support and grants distributed through A/B/C/D group call programs, and healthcare service fees generated through TÜSKA accreditation and certification programs. Go-to-market is institution-led and event-driven, with formal collaboration protocols governing university and hospital engagement, and active participation in scientific conferences such as EXPOMED Eurasia and the Turkic World Medical Congress. Geographic footprint is national across Turkey, with international collaboration extending to G20 nations, Turkic states (Uzbekistan, Kazakhstan), and Cuba (BioCubaFarma), positioning TÜSEB as both a domestic health R&D coordinator and a regional diplomatic instrument for Turkish health policy.

Name

Health Institutes of Türkiye

Legal name

Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB)

Website

https://tuseb.gov.tr

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Health Research and Development

NAICS

International Affairs (92812)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Immunization & Vaccination Programs Administration (BPAIAJAD)

akta.pro secondary industry

Global Health Institutes & Programs (EDAHAGAM)

Keywords

• Health research
• Biotechnology development
• Vaccine development
• Clinical research
• Healthcare accreditation

Headquarters

HQ city

Istanbul

HQ country

Türkiye

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Government Budget Allocation: TÜSEB operates as a government institution under the Ministry of Health with annual budget allocations from the Turkish government for health research, institute operations, and project funding.
2. Project Support and Grants: Funding for research projects through various call programs (A, B, C, D groups) supporting universities, researchers, and healthcare institutions in health technology development.
3. Healthcare Service Fees: Revenue from accreditation services through TÜSKA (Healthcare Quality and Accreditation Institute) and certification programs for healthcare facilities.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Core offering

Health Institutes of Türkiye (TÜSEB) is a government institution that coordinates Turkey's health research and development ecosystem through 9 specialized institutes and 4 research centers. It funds health research projects, conducts biotechnology and vaccine R&D (including TURKOVAC and CAR-T cell therapy), operates Technology Transfer Offices for commercialization, and delivers healthcare quality accreditation through TÜSKA.

Product overview

Health Institutes of Türkiye (TÜSEB) is a government health research and development institution operating under Turkey's Ministry of Health. The organization functions as a platform comprising 9 specialized institutes (TACESE, TAE, TBE, TÜGET, TÜHKE, TKE, TÜSKA, TÜSPE, TUYZE) and 4 research centers (TUGEM, BİYAŞAM, ASAM, İDEA), supported by core systems including TBYS (project management), TTO (technology transfer), project support programs (A/B/C/D groups), and the TURKOVAC vaccine. The institutes cover maternal-child health, vaccines, biotechnology, traditional medicine, public health, cancer, quality accreditation, health policy, and health data/AI. The portfolio includes scientific publications (TÜSEB Dergisi), project funding mechanisms, technology commercialization support, and recognition programs (TÜSEB Awards).

Differentiator

Problem solved

Functional benefit

Brands

• JHIT - Journal of Health and Innovation Technologies: TÜSEB's official scientific journal publishing health research articles
• TURKOVAC
• TÜSEB Bilgi ve Yönetim Sistemi (TBYS)
• TÜSEB TTO
• AkademiKA

Products and services

• TURKOVAC COVID-19 Vaccine
• CAR-T Cell Therapy Production
• Color Doppler Ultrasonography Device Development Project
• TÜSEB Project Support Programs (A/B/C/D Group Calls)
• TÜSEB Technology Transfer Office (TTO) Services
• TÜSKA Healthcare Quality Accreditation
• TÜSEB Information and Management System (TBYS)
• JHIT – Journal of Health Institutes of Türkiye (TÜSEB Dergisi)

Quantifiable outcome

• Successfully completed TURKOVAC indigenous COVID-19 vaccine development
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

20 partnerships are on record, tiered core and strategic.

• ARTED (Research Medical Technologies Manufacturers Association)coreStrategic or Co-development Partner · 29 July 2026Protocol for medical device sector collaboration including information sharing, training development, and technology-oriented cooperation. Aims to strengthen local medical device production.
• TİKA (Turkish Cooperation and Coordination Agency)strategicStrategic or Co-development Partner · 23 July 2026Discussions on health service collaboration, scientific studies, and capacity building for Turkic states. Part of regional health diplomacy initiatives.
• Ankara UniversitycoreStrategic or Co-development Partner · 21 July 2026Collaboration protocol to strengthen cooperation in health sciences and research. Signed by TÜSEB President Prof. Dr. Ümit Kervan and Ankara University Rector Prof. Dr. Necdet Ünüvar.
• IQVIAcoreTechnology or Integration · 30 June 2026Collaboration agreement for clinical research, technology, market research, analytics, and consulting. Supports TÜSEB's data-driven decision making and health technology assessment capabilities.
• Novo Nordisk TurkeycoreStrategic or Co-development Partner · 24 June 2026Strategic partnership protocol under TÜSEB's 'Producing Health' vision to accelerate Turkish researchers' integration into global scientific networks and facilitate patient access to innovative treatments.
• Pfizer TurkeycoreStrategic or Co-development Partner · 11 June 2026Collaboration protocol signed in Ankara for strengthening clinical research capacity in Turkey, improving collaboration between research centers, and supporting international standards implementation.
• UzbekistanstrategicStrategic or Co-development Partner · 5 June 2026Online meeting with Uzbekistan representatives to explore biopharmaceutical and health sciences academic collaboration opportunities.
• Roche TurkeycoreStrategic or Co-development Partner · 1 June 2026Partnership protocol for developing clinical research and strengthening Turkey's position in international clinical research ecosystem. Covers feasibility support for clinical studies, identifying research centers, ethics committee processes, city hospital collaborations, and Good Clinical Practice training.
• Istanbul Chamber of Industry (İSO)coreStrategic or Co-development Partner · 1 June 2026Joint 'Localization in Health and Strategic Cooperation Event' to promote local production capacity and public-private collaboration in health technologies.
• Sanofi TurkeycoreStrategic or Co-development Partner · 20 May 2026TÜSEB and Sanofi signed two protocols covering health innovation, chronic diseases management, and clinical research. Collaboration aims to strengthen R&D capacity, support entrepreneurship, provide training, and promote international clinical research standards in Turkey. Includes AkademiKA training program for Good Clinical Practices.
• Pamukkale UniversitycoreStrategic or Co-development Partner · 28 April 2026Comprehensive collaboration protocol covering vaccines, cancer, clinical research, biomedical technologies, biotechnology, drug delivery systems, medical devices, AI, biomaterials, medical imaging, and diagnostic kits.
• Neuroscience and Neurotechnology Center of Excellence (NÖROM)coreStrategic or Co-development Partner · 22 April 2026Protocol with Gazi University covering cancer, clinical studies, biomedical technologies, biotechnology, drug delivery, medical devices, AI, biomaterials, medical imaging, and diagnostic kits.
• Institute for Health Metrics and Evaluation (IHME)coreStrategic or Co-development Partner · 20 April 2026Training collaboration on Global Burden of Disease (GBD) data usage covering health indicators, comparative analyses, and policy applications. Conducted with international experts Prof. Dr. Mohsen Naghavi and Prof. Dr. Enis Barış.
• Ege UniversitycoreStrategic or Co-development Partner · 10 April 2026Protocol for establishing TÜSEB Izmir Campus within the university. Represents TÜSEB's expansion to western Turkey with research infrastructure.
• Global Coalition (Dengue)strategicStrategic or Co-development Partner · 8 April 2026Turkey's contribution through TÜSEB to global coalition's first dengue-focused project call, supporting equitable access to health technologies.
• BioCubaFarma (Cuba)strategicStrategic or Co-development Partner · 3 April 2026High-level visit by Cuban Embassy officials representing BioCubaFarma for ongoing collaboration in pharmaceuticals and biotechnology.
• Middle East Technical University (ODTÜ)coreStrategic or Co-development Partner · 2 April 2026Strategic collaboration protocol for health technology research. Includes BAMA Technology Center visit and technology transfer initiatives.
• Kazakhstan - Salidat Kairbekova National Health Development Scientific CenterstrategicStrategic or Co-development Partner · 2 April 2026Delegation visit to strengthen health sector cooperation between Kazakhstan and Turkey under Turkic States cooperation framework.
• HAVELSANstrategicTechnology or Integration · 17 March 2026Strategic collaboration discussions between TÜSEB President and HAVELSAN General Manager for potential health technology and digital health solutions.
• TÜBİTAKcoreStrategic or Co-development PartnerOngoing collaboration with Turkey's main research funding agency for health research projects and joint initiatives.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• INSERM: France's national institute for health and medical research, the leading European public biomedical research body covering translational science, clinical research, and public health, parallel to TÜSEB's mandate.
• National Institutes of Health (NIH): The US federal agency coordinating biomedical and public health research across multiple institutes and centers. NIH is the most direct analog to TÜSEB's role as a national government health R&D coordinator with intramural labs and extramural grant-making.
• Indian Council of Medical Research (ICMR): India's apex body for biomedical research under the Ministry of Health, operating national institutes and vaccine/biotech programs. ICMR is a near-analog in mandate, scale, and emerging-market context for TÜSEB.
• Oswaldo Cruz Foundation (Fiocruz): Brazilian Ministry of Health-linked institution operating research institutes, vaccine production (including COVID-19 immunizers), and public health labs. Highly comparable to TÜSEB's integrated vaccine + public health + clinical research role.
• TÜBİTAK (Scientific and Technological Research Council of Türkiye): Turkey's main public research funding and execution agency under the Ministry of Industry and Technology, actively collaborating with TÜSEB on health projects. Acts as a domestic peer with overlapping grant-making and applied research mandates.
• Agency for Science, Technology and Research (A*STAR): Singapore's government research agency operating biomedical and clinical sciences institutes with strong industry partnership programs. A*STAR's model of state-funded multi-disciplinary health R&D institutes is structurally analogous to TÜSEB.
• Chinese Academy of Medical Sciences (CAMS): China's main national academy for medical research, encompassing multiple institutes covering vaccines, biotechnology, clinical research, and public health, comparable in structure and scope to TÜSEB's nine-institute model.
• South African Medical Research Council (SAMRC): South Africa's national health research body funding and conducting biomedical and public health research across institutes, comparable to TÜSEB's role as a government-funded research coordinator.

Broad incumbents

• Pasteur Institute: Internationally recognized biomedical research organization with a broad vaccine, infectious disease, and global health portfolio spanning many geographies. Overlaps with TÜSEB on vaccine R&D (e.g., relationship with TAE) but operates at greater scale and geographic breadth.

Regional players

• King Abdullah International Medical Research Center (KAIMRC): Saudi Arabia's main government health research enterprise operating across multiple centers with clinical trial and biotechnology focus. KAIMRC is a regional peer to TÜSEB in the Middle East health R&D ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC
• LinkedInlinkedin.com/company/tusebgovtr

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Health Institutes of Türkiye